Upcoming Medical Policies
BlueCross BlueShield of Tennessee

Each medical policy listed below will become effective on the date indicated, and will be included in the Medical Policy Manual for BlueCross BlueShield of Tennessee on that effective date.

Medical policies are developed using an evidence-based evaluation process.  The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and opinions from appropriate network specialists. All Medical Policies are reviewed by a panel of internal and external physicians before being adopted by the company.

Topics due to be included in the Medical Policy Manual on 10/11/2014

Topics due to be included in the Medical Policy Manual on 11/8/2014

Topics due to be included in the Medical Policy Manual on 11/19/2014

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Topics due to be included in the Medical Policy Manual on 10/11/2014:

Ultrafiltration for Decompensated Heart Failure

Topics due to be included in the Medical Policy Manual on 11/8/2014:

Multi-biomarker Testing for Rheumatoid Arthritis

Topics due to be included in the Medical Policy Manual on 11/19/2014:

Ado-Trastuzumab Emtansine

Certolizumab Pegol

Genetic Testing, Including Chromosomal Microarray Analysis and Next-Generation Sequencing Panels, for Prenatal Evaluation and Evaluation of Children with Developmental Delays/Intellectual Delays or Autism Spectrum Disorder

Proton or Helium Ion Beam (Charged Particle) Radiation Therapy


Last Review Date: 9/15/2014